Social, Structural, and Lifestyle Drivers of Prostate Cancer Disparities
Prostate Cancer (PC) is the most common non-cutaneous malignancy diagnosed and second leading cause of cancer death among men across the United States. PC among Black men accounts for a higher proportion alike of cancer diagnoses and deaths. In the prostate specific antigen (PSA)-based screening era, mortality rates improved at a similar velocity among Black and White men, but the 2- to 3-fold excess mortality burden borne by Black men has persisted over the past 40 years, the second highest among all major cancers. In recent years mortality is rising among Black men, and at a rapid velocity.
The explanations for this disparity-the extent to which it is attributable to genetics, environmental factors including Structural and Social Determinants of Health (SSDH), or access to care-are multifactorial and have been elucidated to a limited extent. A large meta-analysis recently found that across dozens of studies and cohorts, greater adjustment for clinical and SSDH factors generally resulted in race itself dropping as a significant predictor.
These and other findings suggest that the determinants of disparity be identified at time of, and prior to, cancer diagnosis, and that both genetic and environmental factors contribute to earlier development and progression.
調査の概要
詳細な説明
The investigators hypothesize that SSDH factors drive cancer development differentially by race, and including SSDH factors in prediction models can improve risk prediction to guide decision-making regarding screening, diagnosis, and treatment across race and ethnic groups.
PRIMARY OBJECTIVE:
To identify not yet discovered SSDH and lifestyle factors that associate with identification of unfavorable vs. favorable prostate cancer histology between Black, Hispanic, and Asian men.
OUTLINE:
UCSF participants who agreed to participate in the Urology 90991 Biobank Consent (UCSF internal review board (IRB) #11-05226), and urology surgeons at community hospitals may refer participants for radical prostatectomy to University of California, San Francisco. Potential participants will be approached by the UCSF study team for an offer to participate and Non-UCSF participants will be asked to sign a medical release form prior to the research team collecting data from your medical record about your prostate cancer and treatment.
研究の種類
入学 (推定)
連絡先と場所
研究連絡先
- 名前：Kiana Washington
- 電話番号：415.514.8026
- メール：Kiana.Washington@ucsf.edu
研究連絡先のバックアップ
- 名前：Karina Acevedo
- 電話番号：415.353.7615
- メール：Karina.Acevedo@ucsf.edu
研究場所
-
-
California
-
San Francisco、California、アメリカ、94143
- 募集
- University of California, San Francisco
-
コンタクト：
- Kiana Washington
- 電話番号：415.514.8026
- メール：Kiana.Washington@ucsf.edu
-
コンタクト：
- Karina Acevedo
- 電話番号：415.353.7615
- メール：Karina.Acevedo@ucsf.edu
-
主任研究者：
- Mathew Cooperberg, MD, MPH
-
-
参加基準
適格基準
就学可能な年齢
- 大人
- 高齢者
健康ボランティアの受け入れ
サンプリング方法
調査対象母集団
説明
Inclusion Criteria:
- Participants who have elected radical prostatectomy as prostate cancer treatment.
- Participants who have agreed to participate in the Urology Biobank.
Exclusion Criteria:
- Participant does not plan nor schedule a radical prostatectomy (RP) procedure.
研究計画
研究はどのように設計されていますか？
デザインの詳細
コホートと介入
グループ/コホート |
介入・治療 |
|---|---|
|
Men with prostate cancer
Participants who have planned or completed a non-investigational radical prostatectomy will be asked to complete a series of questionnaires online covering a subset of community-informed SSDH measures and individual exposures.
Responses will be recorded in a secured database. .
It will take about up to 2 hours to complete the surveys.
There will be questions about your demographics (education level, income, employment, etc.); health care access and quality; lifestyle and behaviors.
Data from your medical record about your prostate cancer and treatment will also be collected.
|
Participants will receive surveys to complete online via a secure system.
他の名前：
Data will be collected from participants medical charts which includes disease history, pathological findings, and other disease characteristics.
他の名前：
|
この研究は何を測定していますか？
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Identification of not yet identified factors contributing to prostate cancer
時間枠：Up to 2 years
|
Genomic and SSDH factors will be evaluated to locate not yet identified factors that are associated with greater immune activation and prediction of unfavorable vs. favorable prostate cancer biology by race and ethnicity groups.
|
Up to 2 years
|
協力者と研究者
捜査官
- 主任研究者：Matthew Cooperberg, MD、University of California, San Francisco
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
キーワード
追加の関連 MeSH 用語
その他の研究ID番号
- 255517
- U54CA302452 (米国 NIH グラント/契約)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
IPD 共有サポート情報タイプ
- STUDY_PROTOCOL
- SAP
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。